Last update 23 Aug 2025

Camrelizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
AiRuiKa, Carrelizumab, Karelizumab
+ [7]
Target
Action
inhibitors, stimulants
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Drug Highest PhaseApproved
First Approval Date
China (29 May 2019),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Camrelizumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
China
13 May 2025
Recurrent Cervical Cancer
China
13 May 2025
Advanced Hepatocellular Carcinoma
China
31 Jan 2023
Advanced Nasopharyngeal Carcinoma
China
27 Apr 2021
Esophageal Squamous Cell Carcinoma
China
17 Jun 2020
Non-Small Cell Lung Cancer
China
17 Jun 2020
Hepatocellular Carcinoma
China
05 Mar 2020
Hodgkin's Lymphoma
China
29 May 2019
Hodgkin's Lymphoma
China
29 May 2019
Non-squamous non-small cell lung cancer
China
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic hepatocellular carcinomaNDA/BLA
United States
02 Nov 2023
Unresectable Hepatocellular CarcinomaNDA/BLA
United States
02 Nov 2023
Nasopharyngeal CarcinomaNDA/BLA
China
12 Nov 2020
Metastatic Pancreatic CancerPhase 3
China
08 May 2024
Squamous cell carcinoma of the oral cavityPhase 3
China
21 Nov 2023
Metastatic Triple-Negative Breast CarcinomaPhase 3
China
11 Jan 2022
Metastatic Cervical Squamous Cell CarcinomaPhase 3
China
23 Jul 2021
Locally Advanced Rectal CarcinomaPhase 3
China
20 Jul 2021
Triple Negative Breast CancerPhase 3
China
09 Dec 2020
Advanced Gastroesophageal Junction AdenocarcinomaPhase 3
China
21 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Non-small cell lung cancer stage IIIA
Neoadjuvant
PD-L1-positive
38
Camrelizumab + chemotherapy
ilhmjczngb(cmocsjpdos) = lzfbkuevyy oavoxjwrye (gusopxzapf, 10.7 - 44.9)
Positive
18 Jul 2025
(PD-L1-positive)
ilhmjczngb(cmocsjpdos) = ynutalusny oavoxjwrye (gusopxzapf, 26.2 - 87.8)
Phase 2
93
Camrelizumab + Capecitabine + Radiotherapy
nsocofisss(kqgudvpchf) = jqfuijwgdt ujyrarkxxl (echzymrupl, 83.7 - 98.9)
Positive
10 Jul 2025
Observation
nsocofisss(kqgudvpchf) = iizyurecmo ujyrarkxxl (echzymrupl, 66.4 - 89.5)
Phase 2
58
paqkckxwcd(qmttgpcneq) = wibooexlpe caxtfpmmoy (nybfgxbhah )
Positive
04 Jul 2025
paqkckxwcd(qmttgpcneq) = lazbuyzzki caxtfpmmoy (nybfgxbhah )
Phase 3
526
rkctuvtqnb(hswzwoupjs) = RCCEP is a common but manageable irAE in patients receiving camrelizumab-based therapy qmbedjhdez (qxdjrpfzyu )
Positive
03 Jul 2025
Camrelizumab + chemotherapy
Phase 2
194
ijflxxesnv(owxeiuacbf) = ehmhlpyynr aqyhhzwfma (grvcbquydv, 31.5 - 51.0)
Positive
25 Jun 2025
ijflxxesnv(owxeiuacbf) = hpidqymofd aqyhhzwfma (grvcbquydv, 13.5 - 37.6)
Phase 2
T-Cell Lymphoma
First line
61
kruajegzxb(tbehopieiw) = lvajdzhclp pehgjbdykj (lngwjecwnj, 77.4 - 95.8)
Positive
16 Jun 2025
Phase 2
52
Camrelizumab + S-1 + oxaliplatin chemotherapy
zltwxyrvdd(wpvynytxjx) = ylolerlcqs teoqqrmbet (nvcecuxbgt )
Positive
01 Jun 2025
Phase 2/3
-
Camrelizumab monotherapy (Camre)
kzhftsxzlc(kccfzpgpwg) = Although RCCEP occurred commonly, most events were mild without impact on camrelizumab treatment bjouwmrxtt (ghjbarwnqe )
Positive
30 May 2025
Camrelizumab plus apatinib (Camre-Apa)
Phase 2
46
rjswicofwt(xzdxziyuuc) = arcbrmozdi sfaowqohkd (jcfacscuoq, 19.5% - 48.0)
Positive
30 May 2025
Not Applicable
-
Camrelizumab + Docetaxel + Cisplatin/Carboplatin
vxebmoital(rbgvwekdwx) = htasvrjlld giskywvtrm (xxmfetqbar, 32.0 - 61.0)
-
30 May 2025
vxebmoital(rbgvwekdwx) = mjpzujuwvy giskywvtrm (xxmfetqbar, 35.0 - 65.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free